Comparison · NCT04091087-sae
Crisaborole 2% Ointment vs Vehicle Ointment: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Crisaborole 2% Ointment vs Vehicle Ointment: serious adverse events. Trial comparisons, record NCT04091087-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04091087-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0303 | 0.00537 | 0.153 | wilson | |
| Risk in group 2 | 0.125 | 0.0497 | 0.281 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0947 | -0.252 | 0.0494 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.242 | 0.0286 | 2.05 | log | |
| Odds ratio, group 1 over group 2 | 0.219 | 0.0231 | 2.07 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Crisaborole 2% Ointment than on Vehicle Ointment | 10.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Crisaborole 2% Ointment | Participants applied crisaborole ointment 2% topically BID to the stasis dermatitis affected lower extremities (knees to feet) for 6 weeks. Participants were followed-up for 4 weeks after treatment completion. | 1 | 33 | EG001 |
| Group 2 | Vehicle Ointment | Participants applied vehicle ointment topically BID to the stasis dermatitis affected lower extremities (knees to feet) for 6 weeks. Participants were followed-up for 4 weeks after treatment completion. | 4 | 32 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 up to maximum of 4 weeks after the last dose (maximum for 10 weeks)
Source ClinicalTrials.gov
Trial
- Title
- Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
- NCT number
- NCT04091087
- Phases
- PHASE2
- Conditions
- Stasis Dermatitis
- Interventions
- crisaborole ointment, vehicle ointment
- Lead sponsor
- Pfizer
- Results first posted
- 2022-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04091087?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04091087-sae